- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01080040
To Assess the Prevalence of Spasticity and the Impact on the Quality of Life in Multiple Sclerosis Patients
Observational Study to Assess the Prevalence of Spasticity and the Impact on the Quality of Life in Patients With Multiple Sclerosis in Argentina
This study is observational, non-controlled, multicentric and prospective, without experimental intervention or control. As part of the usual management of the subjects, scales will be used for the assessment of the spasticity and the quality of life (QoL).
The purpose of this observational study is to assess the incidence of spasticity in a group of subjects with Relapsing Remitting Multiple Sclerosis (RRMS) in Argentina and the way it affects the QoL of these subjects.
Studieoversikt
Status
Detaljert beskrivelse
One of most frequently observed symptoms in subjects with MS is spasticity. Spasticity is defined as an abnormal velocity-dependent increase in muscle tonic stretch reflexes due to an amplified reactivity of motor segments to sensory input. It is part of one of the components of the superior motoneurone syndrome and it may cause muscle rigidity and disability.
The spasticity, which could be measured in electrophysiological, biomechanical and clinical terms, has a significant prevalence. It is a frequent cause for consultation among subjects with MS and, consequently, has a significant impact on the QoL. Men and those subjects with MS of longer duration are the most affected by spasticity.
The aim of this study is to assess the impact that spasticity has on the QoL of subjects with MS.
The total duration of the study is 24 months. The recruiting period will be 12 months. Once the recruiting time is over, the collection of data will continue during the full 24 months period that was planned.
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
-
Rosario, Argentina
- Fundacion Rosarina de Neurorehabilitacion
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Subjects aged from 21 60 years of age
- Subjects with established diagnosis of RRMS according to the revised McDonald criteria - 2005
- Subjects with a diagnosis of RRMS for more than one year
- The subject who have signed the Informed Consent
Exclusion Criteria:
- Subjects with other causes of spasticity
- Subjects with other clinical forms of MS (different from relapsing-remitting)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Assess the prevalence of spasticity in subjects with RRMS
Tidsramme: Initial visit (Day 0) to 24 months
|
Ashworth Scale (AS) (Spasticity) Expanded Disability status scale (EDSS) SF 36
|
Initial visit (Day 0) to 24 months
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Evaluation of the impact of spasticity on the quality of life of subjects with RRMS
Tidsramme: Initial visit (Day 0) to 24 months
|
Initial visit (Day 0) to 24 months
|
Evaluation of the changes in spasticity after 24 months
Tidsramme: Initial visit (Day 0) to 24 months
|
Initial visit (Day 0) to 24 months
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Dr. Jose A. Brizuela, Fundación Rosarina de Neurorehabilitación. Rosario, Argentina.
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- EMR200077-507
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Multippel sklerose, tilbakefallende remittering
-
CinnagenFullførtMultippel sklerose | Relapsing-RemittingIran, den islamske republikken
-
Novartis PharmaceuticalsFullførtMultippel sklerose | Relapsing-RemittingTyrkia
-
EMD SeronoAvsluttetMultippel sklerose | Relapsing-RemittingForente stater
-
National Institute of Allergy and Infectious Diseases...Autoimmunity Centers of ExcellenceAvsluttetMultippel sklerose (MS) - Relapsing-remittingForente stater
-
EMD SeronoMerck Serono International SAFullførtMultippel sklerose, relapsing-remitting
-
Asuman KucukonerFullførtMultippel sklerose-Relapsing-RemittingTyrkia
-
Nantes University HospitalHar ikke rekruttert ennåMultippel sklerose, relapsing-remitting
-
Johns Hopkins UniversityUniversity of California, San Francisco; National Multiple Sclerosis SocietyFullførtMultippel sklerose, relapsing-remittingForente stater
-
McGill UniversityNovartisFullførtMultippel sklerose-Relapsing-RemittingCanada